- Earlier this week, Raymond James attended Haemonetics Corp’s (NYSE:HAE) Investor Day, where the management team presented a new Long-Range Plan (LRP), including some upside on the profitability, outlining each business unit’s positioning and pipeline.
- According to the analysts, the plan implies an upside to expectations, despite some conservatism and back-end weight.
- Raymond James rolled the FY25 EPS estimate of $3.80 vs. the sub-$3.50 consensus into the event.
- See the investor presentation here.
- Though plasma was a major part of the discussion, the team highlighted the other portions of the business that can be viewed as moving towards a more diversified player.
- The analysts note that vascular closure and hemostasis management are poised for more growth and offer a core set of offerings to build both organically and inorganically.
- At ~14x CY22 EBITDA and ~22x CY22 EPS, Raymond James thinks the stock remains attractive in the context of stable growth, with Outperform rating unchanged and the price target raised from $63 to $76 (15% upside).
- The analysts believe Haemonetics is positioned for healthy double-digit earnings growth underappreciated at current valuations.
- Price Action: HAE shares are up 1.18% at $65.95 during the market session on the last check Friday.
6 Analysts Have This to Say About Ventyx Biosciences
Within the last quarter, Ventyx Biosciences (NASDAQ:VTYX) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
